Acute dystonic reaction in an elderly patient with mood disorder after titration of paroxetine: Possible mechanisms and implications for clinical care

Journal of Psychopharmacology

Volumn 16, Issue 4, 2002, Pages 395-397

  Arnone, D ^a,c   Hansen, L ^b   Kerr, J S ^a  

^a Department of Psychiatry   (Australia)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Extra pyramidal side effects; Mood disorders; Movement disorders; Neuroplasticity of aging neurons; Paroxetine; Selective serotonin reuptake inhibitors; Subcortical motor areas

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PROCYCLIDINE; REBOXETINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; DRUG DERIVATIVE; MORPHOLINE DERIVATIVE; PIRENZEPINE;

AGED; ANIMAL EXPERIMENT; ARTICLE; CASE REPORT; DEPRESSION; DOPAMINERGIC SYSTEM; DRUG MECHANISM; DRUG RECEPTOR BINDING; DYSTONIA; ELECTROCONVULSIVE THERAPY; EXTRAPYRAMIDAL SYMPTOM; GERIATRIC PATIENT; GERONTOPSYCHIATRY; HUMAN; MALE; MENTAL DISEASE; MOOD DISORDER; MOTOR DYSFUNCTION; NONHUMAN; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; QUALITY OF LIFE; RAT; SEDATION; SEROTONINERGIC SYSTEM; SIDE EFFECT; SUICIDE; TREATMENT OUTCOME; BIPOLAR DISORDER; CHEMICALLY INDUCED DISORDER; PSYCHOLOGICAL ASPECT;

AGED; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; DYSTONIC DISORDERS; ELECTROCONVULSIVE THERAPY; HUMANS; MALE; MORPHOLINES; PAROXETINE; PIRENZEPINE;

EID: 0036905949     PISSN: 02698811     EISSN: None     Source Type: Journal    
DOI: 10.1177/026988110201600418     Document Type: Article

References (33)

1. Altshulter L L, Pierre J M, Wirshing W C, et al. (1994) Sertraline and akathisia. J Clin Psychopharmacol 14: 278-279
2. Arya D K, McKenzie J, Worrall N (1995) Exacerbation of extra pyramidal symptoms with paroxetine. Aust NZ J Psychiatry 29: 51-52
3. Azmitia E C (1978) The serotoninergic-producing neurons of the midbrain median and dorsal raphe nuclei. In Iversen L L, Iversen S D, Snyder S H (eds), Handbook of Psychopharmacology, Vol. 9: Chemical Pathways in the Brain, pp. 233-314. Plenum Press, New York
4. Baldassano C F, Truman C J, Nierenberg A, Ghaemi S N, Sachs G S (1996) Akathisia: A review and case report following paroxetine treatment. Compr Psychiatry 37: 122-124
5. Baldessarini R J, Marsch E (1990) Fluoxetine and side effects. Archs Gen Psychiatry 47: 191-192
6. Baldwin D, Fineberg N, Montgomery S (1991) Fluoxetine, fluvoxamine and extrapyramidal tract disorders. Int Clin Psychopharmacol 6: 51-58
7. Blier P, Montigny C, Chaput Y (1990) A role for the serotonin system in the mechanism of action of antidepressants. J Clin Psychiatry 51: 14-20
8. Bouchard R H, Poucher E, Vincent P (1989) Fluoxetine and extra pyramidal side effects. Am J Psychiatry 146: 1352-1353
9. Byerley W F, McConnell E J, McCabe R T, Dawson T M, Grosser B I (1988) Decreased beta-adrenergic receptors in rat brain after chronic administration of the selective rerotonin reuptake inhibitor fluoxetine. Psychopharmacology 94:141-143
10. Caley C F (1998) Extra pyramidal reactions from concurrent SSRI and atypical antipsychotic use. Int J Psychiatr Med 15: 76-79
11. Caley C F, Friedman J H (1992) Does fluoxetine exacerbate Parkinson's disease? J Clin Psychiatry 53: 278-282
12. Davies J, Tonogroach P (1978) Neuropharmacologic studies on the nigro striatal and raphe striatal system in the rat. Eur J Pharmacol 51: 91-100
13. Dray A (1981) Serotonin in the basal ganglia: Functions and interactions with other neuronal pathways. J Physiol (Paris) 77: 393-403
14. Edwards J G, Anderson I (1999) Systematic review and guide to selection of selective serotonin reuptake inhibitors. Drugs 57: 507-533
15. Faherty C J, Harkin A J, Leonard B E (1998) The functional sensitisation of sigma receptors following chronic selective reuptake inhibitor treatment. Eur J Pharmacol 346: 15-21
16. Farragher B, Walsh N (1997) Delayed onset of extra pyramidal side effects on combining paroxetine with risperidone. Int J Psychiatr Med 14: 117-118
17. Fibiger H C, Lloyd K G (1984) Neurobiological substrates of tardive dyschinesia: The GABA hypothesis. Trends Neurosci 7: 462-464
18. Hansen L (2002) A critical review of akathisia and in possible association with suicide. Hum Psychopharmacol, in press
19. Hoaken P C S (1995) An alert to extrapyramidal side effects from SSRI's. Can J Psychiatry 40:51
20. Johnson A M (1991) The comparative pharmacological properties of selective serotonin reuptake inhibitors in animal. In Feighner J P, Boyer W F (eds), Selective Serotonin Reuptake Inhibitors. Perspectives in Psychiatry, vol. 1, pp. 37-70. John Wiley, Chirchester
21. Klimek V, Nielson M (1987) Chronic treatment with antidepressants decreases the number of (3H) SCH23390 binding sites in rat striatum and limbic system. Eur Pharmacol 139: 163-169
22. Lauterbach E C (1994) Reversible intermittent rhytmic myoclonus with fluoxetine in presumed Pick's disease. Mov Disord 9: 343-346
23. Leitner M L, Hohmann A G, Patrick S L, Walker J M (1994) Regional variation in the ratio of sigma 1 to sigma 2 binding in rat brain. Eur J Pharmacol 259: 65-69
24. Leo R J (1996) Movement disorder associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry 57: 449-454
25. Leonard B E, Faherty C J (1996) SSRIs and movement disorders: Is serotonin the culprit? Human Psychopharmacol 11: S75-S82
26. Mander A, McCausland M, Workman B, Flamer H, Christophidis N (1994) Fluoxetine induced dyskinesia. Aust NZ J Psychiatry 28: 328-330
27. Mitchell P B (1994) Selective serotonin reuptake inhibitors: Adverse effects, toxicity and interactions. Adv Drug React Toxic Rev 13: 121-144
28. Nicholson S D (1992) Extra pyramidal side effects associated with paroxetine. West Eng Med J 107: 90-91
29. Prisco S, Esposito E (1995) Differential effects of acute and chronic fluoxetine administration on the spontaneous activity of dopaminergic neurons in the ventral tegmental area. Br J Pharmacol 116:1923-31
30. Shihabuddin L, Rapport D (1994) Sertraline and extrapyramidal side effects. Am J Psychiatry 151: 288
31. Sulser F, Mishra R (1982) Regulation of central noradrenergic receptor function and its relevance to therapy of depression. In Langer SZ, Takahashi R, Briley M (eds), New Vistas in Depression, pp. 37-47. Pergamon Press, Oxford
32. Vetulani J, Antkiewicz-Michaluk L, Rokosz-Pelc A, Pilc A (1984) Alpha up-beta down adrenergic regulation: A possible mechanism of action of antidepressant treatments. Pol J Pharmacol Pharm 36: 231-248
33. Wils V (1992) Extra pyramidal symptoms in a patient treated with fluvoxamine. J Neurol Neurosurgery Psychiatry 55: 330-331